154 / 490
152
SCIENTIFIC PROGRAMME
| PROGRAMME AND EXHIBITION GUIDE
INTERDISCIPLINARY RADIOBIOLOGY
CLINICAL BRACHYTHERAPY PHYSICS
RTT
YOUNG
TUESDAY 3 MAY 2016
Symposium
WBRT FOR BRAINMETASTASES- THE END OF AN ERA?
09:15 - 10:30 | GIALLA
This session will address an actual outline of the efficacy of whole brain radiotherapy (WBRT) in the
treatment of multiple brain metastases. First speaker, Paula Mulvenna, will give an overview of WBRT
including history, aims and toxicities. Additionally, she will shortly present the outcomes of the MRC
QUARTZ trial. Luis Schiappacasse will address the role of stereotactic radiosurgery to treat limited and
extensive brain metastases especially in conjunction with WBRT. Finally, Rafal Dziadziuszko will present
systemic therapies for the treatment of brain metastases originated from lung and breast cancer with
focus on chemotherapy alone or in combination with radiotherapy.
Chair: B. Timmermann (Germany)
Co-chair: D. Greto (Italy)
09:15 > Whole brain radiotherapy for brain metastases - the end of an era?
Speaker: P. Mulvenna (UK)
SP-0587
09:40 > Focal radiotherapy for multiple brain metastases
Speaker: L. Schiappacasse (Switzerland)
SP-0588
10:05 > Role of systemic therapy in the treatment of brain metastases
Speaker: R. Dziadziuszko (Poland)
SP-0589
Symposium
RADIOTHERAPY “AUTOVACCINATION”; WITH SYSTEMIC IMMUNE
MODULATORS FOR MODERN IMMUNOTHERAPY
09:15 - 10:30 | ROOM 4
The current understanding of the impact of radiation therapy on anti tumour immunity has changed
our understanding of tumour resistance to radiotherapy which is no longer perceived as the only conse-
quence of tumour cells intrinsic clonogenic resistance to cell kill.
The interplay between tumour cells and the immune stroma is influenced by cell death triggered by
irradiation which dictates the immunological response. Immune checkpoints inhibitors may increase
tumour response and also propagate systemic anti tumour immune response thus converting the
tumour into an immunogenic hub.
Chair: E. Deutsch (France)
Co-chair: M. Trovo (Italy)
09:15 > Should the combined treatment be part of our field of knowledge?
The 5
th
‘R’ (immune-mediated) rejection of radiobiology
Speaker: P.C. Lara Jimenez (Spain)
SP-0590
09:40 > Radiotherapy for immunotherapy: optimising the doses and fractiona-
tion
Speaker: S. Demaria (USA)
SP-0591